EAGLE-2 and EAGLE-3 Phase III Trials for Gepotidacin Stopped Early for Efficacy Following Pre-Planned Interim Analysis by Independent Data Monitoring Committee

Gepotidacin could be the first new novel oral antibiotic treatment for uncomplicated urinary tract infections in over 20 years GSK plans to submit a New Drug Application for gepotidacin to the US Food and Drug Administration (FDA) in H1...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials